19,222 Shares in Avantor, Inc. (NYSE:AVTR) Bought by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd bought a new stake in shares of Avantor, Inc. (NYSE:AVTR) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,222 shares of the company’s stock, valued at approximately $497,000.

Other hedge funds also recently added to or reduced their stakes in the company. 1832 Asset Management L.P. lifted its holdings in shares of Avantor by 1,634.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock valued at $180,839,000 after buying an additional 8,038,451 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Avantor by 653.0% in the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after acquiring an additional 5,354,678 shares during the period. Sound Shore Management Inc. CT purchased a new stake in Avantor in the 2nd quarter worth approximately $76,412,000. Principal Financial Group Inc. boosted its position in Avantor by 146.5% in the 3rd quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock worth $67,996,000 after purchasing an additional 1,562,018 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of Avantor by 6.8% during the 2nd quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock worth $486,059,000 after purchasing an additional 1,463,695 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is owned by corporate insiders.

Avantor Price Performance

Shares of NYSE AVTR opened at $21.04 on Friday. The firm has a 50-day simple moving average of $23.40 and a 200-day simple moving average of $23.76. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $14.32 billion, a price-to-earnings ratio of 45.74, a price-to-earnings-growth ratio of 2.56 and a beta of 1.35. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00.

Wall Street Analyst Weigh In

AVTR has been the subject of several analyst reports. UBS Group decreased their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company dropped their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.